Drug Trial Radar · NCT03212404
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
272
Actual
Start
Sep 20, 2017
Primary completion
Nov 18, 2021
Study completion Dec 2025
Sponsor
- Lead sponsor
- Checkpoint Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Jul 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.
Conditions
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- Malignant Mesothelioma, Advanced
- Head and Neck Cancer
- Melanoma
- Merkel Cell Carcinoma
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Classical Hodgkin Lymphoma
- Cutaneous Squamous Cell Carcinoma
- Non Hodgkin Lymphoma
- Endometrial Cancer
Interventions
CK-301 (cosibelimab)Drug
CK-301 will be administered in periods of 28-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting ToxicityTime frame: Up to 4 weeks
- Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version)Time frame: Screening through 4 weeks after study completion, an average of 6 months
- Confirmed Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)Time frame: Part 2 Only: Average of 6 months
Locations
48 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Wollongong, New South Wales, Australia
Research Site
Benowa, Queensland, Australia
Research Site
Buderim, Queensland, Australia
Research Site
Greenslopes, Queensland, Australia
Research Site
South Brisbane, Queensland, Australia
Research Site
Woolloongabba, Queensland, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Malvern, Victoria, Australia
Research Site
Besançon, France
Research Site
Bordeaux, France
Research Site
Grenoble, France
Research Site
Lyon, France
Research Site
Nice, France
Research Site
Christchurch, New Zealand
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Poznan, Poland
Research Site
Warsaw, Poland
Research Site
Chelyabinsk, Russia
Research Site
Kazan', Russia
Research Site
Murmansk, Russia
Research Site
Novosibirsk, Russia
Research Site
Omsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Tyumen, Russia
Research Site
Volgograd, Russia
Research Site
Cape Town, South Africa
Research Site
George, South Africa
Research Site
Port Elizabeth, South Africa
Research Site
Pretoria, South Africa
Research Site
Soweto, South Africa
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Pamplona, Spain
Research Site
San Cristóbal de La Laguna, Spain
Research Site
Seville, Spain
Research Site
Valencia, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.